dl309 is an adenovirus type 5 (Ad5) mutant that has been extensively u
tilized for construction of Ad5 mutants in early region 1 (E1), in dev
eloping vectors for use as viral vaccines, and in development of gene
transfer vectors for gene therapy. Ad5 dl309 has been useful for vecto
r construction because of its altered XbaI restriction pattern and len
ds itself to a variety of strategies for rescuing inserts or mutations
into E1. It contains only one XbaI site at 3.7 map units (m.u.) as co
mpared to wt Ad5 which contains 4 (3.7, 29.5, 79.5, and 84.8 m.u.). Th
e loss of the sites at 29.5 and 79.5 m.u. is due to deletions of a few
bp but the loss of the site at 84.8 m.u. was the result of a deletion
from approximately 83 to 85 m.u. and substitution with a fragment of
foreign DNA. Because of the widespread use of dl309 and derivatives of
this mutant in the construction of Ad5-based vectors and the need to
have precise genetic information on the sequences present in vectors t
o be used as vaccines and in gene therapy, we have sequenced the alter
ations in dl309 which affect the XabI sites at 79.5 and 84.8 m.u. and
have determined which E3 proteins are expressed by this virus. The del
etion that removes the XbaI site at 84.8 m.u. extends from Ad5 bp 3000
5-30750 and is substituted with 642-bp of heterologous DNA that shows
homology to salmon DNA. This alteration deletes all or part of the cod
ing sequences for the E3 14.7K, 14.5K and 10.4K proteins and these pro
teins were not detected in dl309 infected cells. The loss of the XbaI
site at 79.5 m.u. is the result of a 6-bp deletion which removes two i
nternal amino acids (18 and 19) from the E3 6.7K protein. The E3 6.7K
protein and other E3 proteins whose coding sequences are unaffected by
the alterations in dl309 (gp19K, 12.5K and 11.6K) were expressed in d
l309 infected cells.